Clinical-pathological Characterization and Outcomes of Metastatic Urothelial Cancer in Latin America
The LACOG 1518 study will characterize demographic and clinical-pathological profile of patients diagnosed with recurrent/ metastatic urothelial cancer in Latin America.
Recurrent/Metastatic Urothelial Cancers
Epidemiology, Overall survival (OS) will be defined from the date of treatment initiation to date of death from any cause. In case of patients that received palliative care only, OS will be defined from date of diagnosis of advanced disease to date of death from any cause. Patients who are alive will be censored at the date of last known contact., 2 years
Socioeconomic chactacteristcs, Health Care Insurance (Public or Private), 2 years|Overall response, Defined as the proportion of patients who have a partial or complete response to therapy according to RECIST 1.1, 2 years|Duration of response, Defined as the time from response to progression by RECIST v11.1 or death, 2 years|PFS, Progression-free survival (PFS) will be defined from date of treatment initiation to date of disease progression or death from any cause, whichever occurs first in each line., 2 years
The LACOG 1518 study will characterize demographic and clinical-pathological profile of patients diagnosed with recurrent/ metastatic urothelial cancer in Latin America.